The Role of Follicular Regulatory T Cells/Follicular Helper T Cells in Primary Immune Thrombocytopenia.


Journal

Acta haematologica
ISSN: 1421-9662
Titre abrégé: Acta Haematol
Pays: Switzerland
ID NLM: 0141053

Informations de publication

Date de publication:
2023
Historique:
received: 25 02 2022
accepted: 22 02 2023
medline: 14 8 2023
pubmed: 15 3 2023
entrez: 14 3 2023
Statut: ppublish

Résumé

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by thrombocytopenia. Herein, we sought to identify potential immune-related therapeutic targets in ITP. The differentially expressed genes (DEGs) between ITP patients and controls in GSE43177 and PRJNA299534 were analyzed. The intersections of the two DEG groups were screened as common genes, and enrichment analysis was performed. Additionally, differential analysis of immune cell levels between ITP and controls was performed. Changes in the proportions of T follicular helper (Tfh) and follicular regulatory T (Tfr) cells in peripheral blood samples from ITP patients, ITP patients responding to therapy, and healthy controls were identified. The expression changes in B-cell lymphoma (Bcl)-6 and interleukin (IL)-21 were further evaluated. A total of 76 common genes were identified, and enrichment analysis found that these genes were mainly associated with neutrophil-mediated immunity, the MAPK signaling pathway, and the FOXO signaling pathway. Furthermore, we found different levels of Tfh cells in patients with ITP and controls. The level of Tfh cells in the peripheral blood is significantly increased in ITP patients and declines after responding to therapy. The Tfr/Tfh ratio was reduced in ITP patients and increased after responding to therapy. IL-21 and Bcl-6 were more highly expressed in ITP patients than in controls. We identified abnormally expressed genes in ITP related to immune-related biological functions. We further identified the changes in Tfh and Tfr cells during ITP treatment. This provides a rationale for immunotherapy in ITP patients.

Identifiants

pubmed: 36917965
pii: 000529963
doi: 10.1159/000529963
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

267-276

Informations de copyright

© 2023 S. Karger AG, Basel.

Auteurs

Mingling Sun (M)

Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi, China.

Xiujuan Wang (X)

Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Lei Wang (L)

Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Xinyou Wang (X)

Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Wenxia Fan (W)

Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Ying Liu (Y)

Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Qinzhi Li (Q)

Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Ning Zhang (N)

Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Xinhong Guo (X)

Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH